Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;89(5):1268-1277.
doi: 10.1038/s41390-020-1037-9. Epub 2020 Jul 22.

The bioavailability and maturing clearance of doxapram in preterm infants

Robert B Flint  1   2   3 , Sinno H P Simons  4 , Peter Andriessen  5 , Kian D Liem  6 , Pieter L J Degraeuwe  7 , Irwin K M Reiss  4 , Rob Ter Heine  8 , Aline G J Engbers  9 , Birgit C P Koch  10 , Ronald de Groot  11 , David M Burger  8 , Catherijne A J Knibbe  9   12 , Swantje Völler  9 ; DINO Research Group
Collaborators, Affiliations

The bioavailability and maturing clearance of doxapram in preterm infants

Robert B Flint et al. Pediatr Res. 2021 Apr.

Abstract

Background: Doxapram is used for the treatment of apnea of prematurity in dosing regimens only based on bodyweight, as pharmacokinetic data are limited. This study describes the pharmacokinetics of doxapram and keto-doxapram in preterm infants.

Methods: Data (302 samples) from 75 neonates were included with a median (range) gestational age (GA) 25.9 (23.9-29.4) weeks, bodyweight 0.95 (0.48-1.61) kg, and postnatal age (PNA) 17 (1-52) days at the start of continuous treatment. A population pharmacokinetic model was developed using non-linear mixed-effects modelling (NONMEM®).

Results: A two-compartment model best described the pharmacokinetics of doxapram and keto-doxapram. PNA and GA affected the formation clearance of keto-doxapram (CLFORMATION KETO-DOXAPRAM) and clearance of doxapram via other routes (CLDOXAPRAM OTHER ROUTES). For a median individual of 0.95 kg, GA 25.6 weeks, and PNA 29 days, CLFORMATION KETO-DOXAPRAM was 0.115 L/h (relative standard error (RSE) 12%) and CLDOXAPRAM OTHER ROUTES was 0.645 L/h (RSE 9%). Oral bioavailability was estimated at 74% (RSE 10%).

Conclusions: Dosing of doxapram only based on bodyweight results in the highest exposure in preterm infants with the lowest PNA and GA. Therefore, dosing may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. For switching to oral therapy, a 33% dose increase is required to maintain exposure.

Impact: Current dosing regimens of doxapram in preterm infants only based on bodyweight result in the highest exposure in infants with the lowest PNA and GA. Dosing of doxapram may need to be adjusted for GA and PNA to minimize the risk of accumulation and adverse events. Describing the pharmacokinetics of doxapram and its active metabolite keto-doxapram following intravenous and gastroenteral administration enables to include drug exposure to the evaluation of treatment of AOP. The oral bioavailability of doxapram in preterm neonates is 74%, requiring a 33% higher dose via oral than intravenous administration to maintain exposure.

PubMed Disclaimer

References

    1. Poets, C. F. et al. Association between intermittent hypoxemia or bradycardia and late death or disability in extremely preterm infants. JAMA 314, 595–603 (2015). - PubMed - DOI
    1. Sawyer, T. et al. Improving neonatal intubation safety: a journey of a thousand miles. J. Neonatal Perinat. Med. 10, 125–131 (2017). - DOI
    1. Sweet, D. G. et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome—2016 update. Neonatology 111, 107–125 (2017). - PubMed - DOI
    1. Morton, S. U. & Smith, V. C. Treatment options for apnoea of prematurity. Arch. Dis. Child Fetal Neonatal Ed. 101, F352–F356 (2016). - PubMed - DOI
    1. Schmidt, B. et al. Caffeine therapy for apnea of prematurity. N. Engl. J. Med. 354, 2112–2121 (2006). - PubMed - DOI

Publication types

LinkOut - more resources